Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | SDHB | P21912 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6734903 | 0.89 | PTGS2 (0.40) | NR1H2NR1H3PDE3BPDE3APTGS2 | |
| SCHEMBL6729586 | 0.88 | PTGS2 (0.34) | PTGS2 | |
| SCHEMBL6733002 | 0.88 | ACLY (0.41) | NR1H2NR1H3PTGS2ACLYPTGS1 | |
| SCHEMBL6739952 | 0.87 | RAB9A (0.38) | NR1H2NR1H3PTGS2ACLYPTGS1 | |
| SCHEMBL6731867 | 0.87 | NR1H2 (0.34) | NR1H2NR1H3PTGS2ACLYPTGS1 | |
| SCHEMBL6732652 | 0.87 | PTGS2 (0.45) | PTGS2PTGS1 | |
| SCHEMBL6736835 | 0.85 | NR1H2 (0.39) | NR1H2NR1H3PTGS2AKR1C3AKR1C2 | |
| SCHEMBL6737139 | 0.85 | PTGS2 (0.38) | PDE3BPDE3APTGS2AKR1C3AKR1C2 | |
| SCHEMBL6735812 | 0.85 | PTGS2 (0.46) | PDE3BPDE3APTGS2PTGS1 | |
| SCHEMBL6733271 | 0.85 | PTGS2 (0.46) | NR1H2NR1H3PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-6673818-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER | PHARMACIA CORPORATION | 2004-01-06 | — | — | US | disclosed |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1251126-A2 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | Pharmacia Corporation (US) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138261-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | NR1H2 173/4885NR1H3 299/4885PDE3B 2821/4885 |
| US-20030149078-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | NR1H2 173/4885NR1H3 299/4885PDE3B 2821/4885 |
| US-20030032657-A1 | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | FPR1, FPR2, FPR3 | NR1H2 173/4885NR1H3 299/4885PDE3B 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.